Opinion
Video
Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data
Author(s):
Key Takeaways
- Abrocitinib and upadacitinib provide alternative mechanisms for disease control in patients previously treated with dupilumab.
- JAK inhibitors may be considered when patients experience inadequate response, loss of efficacy, or adverse effects with dupilumab.
EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis
EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis
EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients
EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis
EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice
EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis
EP: 7.Speed of Itch Relief in Atopic Dermatitis
EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis
EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis
Now Viewing
EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data
Video content above is prompted by the following:
- Can you discuss disease control with abrocitinib or upadacitinib in patients previously treated with dupilumab?
- When would you switch a patient to a JAK inhibitor?
Related Videos
Related Content
